NYSEARCA:PBE Invesco Biotechnology & Genome ETF (PBE) Price, Holdings, & News → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free PBE Stock Alerts $60.39 +0.54 (+0.90%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$59.89▼$60.6250-Day Range$59.62▼$67.2952-Week Range$52.47▼$67.76Volume6,904 shsAverage Volume14,615 shsMarket Capitalization$228.87 millionAssets Under Management$243.96 millionDividend Yield0.06%Net Expense Ratio0.58% Stock AnalysisStock AnalysisChartHeadlinesHoldingsOwnershipRatingsStock AnalysisChartHeadlinesHoldingsOwnershipRatings Get Invesco Biotechnology & Genome ETF alerts: Email Address About Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. Invesco PowerShares Capital Management LLC acts as the Fund’s investment adviser.Read More PBE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PBE ETF News HeadlinesMarch 22, 2024 | msn.comInvesco Dynamic Biotechnology & Genome ETF declares quarterly distribution of $0.0242February 19, 2024 | investorplace.com3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough PotentialApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.February 14, 2024 | msn.comWhere Are Biotech ETFs Headed After Q4 Earnings?December 22, 2023 | uk.investing.comInvesco MSCI USA ESG Universal Screened UCITS ETF USD DistributionDecember 14, 2023 | uk.investing.comInvesco Markets plc - Invesco S&P China A 300 Swap UCITS ETFNovember 27, 2023 | lse.co.ukInvesco Nasdaq Biotech Ucits Etf Share Price (SBIO.AM)November 25, 2023 | wsj.comInvesco Biotechnology & Genome ETFApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.November 16, 2023 | lse.co.ukInvesco Msci World Esg Screen Ucits Etf Share Price (ESGW.MI)See More Headlines Receive PBE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invesco Biotechnology & Genome ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerInvesco Fund NameInvesco Biotechnology & Genome ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:PBE Inception Date6/23/2005 Fund ManagerPeter Hubbard, Michael Jeanette, Pratik Doshi, Tony Seisser Webwww.invescopowershares.com Phone+1-800-9830903Fund Focus Asset ClassEquity BenchmarkDynamic Biotech & Genome Intellidex Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings34 Fund Statistics Assets Under Management$243.96 million Average Daily Volume$16,608.90 Discount/Premium0.00% Administrator, Advisor and Custodian AdministratorThe Bank of New York Mellon Corporation AdvisorInvesco Capital Management LLC CustodianThe Bank of New York Mellon Corporation DistributorInvesco Distributors, Inc. Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerCitadel Options OptionableN/A Short Interest9,000 shs Miscellaneous Outstanding Shares3,790,000Beta0.92 Creation Unit10,000 Creation Fee$500.00 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> Invesco Biotechnology & Genome ETF ExpensesTypePBEHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.50%0.56%0.54%0.50%0.51%Other Expenses0.08%0.40%0.54%0.64%0.58%Total Expense0.58%0.72%0.70%0.74%0.70%Fee Waiver0.00%-0.53%-0.55%-0.68%-0.57%Net Expense0.58%0.60%0.60%0.58%0.58% Invesco Biotechnology & Genome ETF (PBE) Holdings & ExposureTop 10 PBE HoldingsNeurocrine Biosciences(NASDAQ:NBIX)Holding Weight: 5.55%Amgen(NASDAQ:AMGN)Holding Weight: 5.08%Vertex Pharmaceuticals(NASDAQ:VRTX)Holding Weight: 5.05%Regeneron Pharmaceuticals(NASDAQ:REGN)Holding Weight: 5.03%BioMarin Pharmaceutical(NASDAQ:BMRN)Holding Weight: 4.95%Biogen(NASDAQ:BIIB)Holding Weight: 4.93%Gilead Sciences(NASDAQ:GILD)Holding Weight: 4.84%Bio-Techne(NASDAQ:TECH)Holding Weight: 4.76%MannKind(NASDAQ:MNKD)Holding Weight: 3.38%Exelixis(NASDAQ:EXEL)Holding Weight: 3.32%PBE Sector ExposurePBE Industry ExposureFull Holdings Details Key ExecutivesH. Bruce BondChairman of the Board of Trustee, Chief Executive OfficerBruce T. DuncanChief Financial Officer, TreasurerKevin R. GustafsonChief Compliance OfficerKeith A OvittSecretaryRonn R. BaggeTrusteeMarc M KoleTrusteeD. Mark McMillanTrusteePhilip M. Nussbaum MbaTrusteeDonald H. WilsonTrusteeMore ExecutivesSimilar ETFsSPDR S&P Health Care Equipment ETFNYSEARCA:XHEInvesco S&P SmallCap Health Care ETFNASDAQ:PSCHInvesco Pharmaceuticals ETFNYSEARCA:PJPSPDR S&P Pharmaceuticals ETFNYSEARCA:XPHDirexion Daily Healthcare Bull 3x SharesNYSEARCA:CUREInstitutional OwnershipYHB Investment Advisors Inc.Bought 1,851 shares on 4/26/2024Ownership: 0.648%Raymond James Financial Services Advisors Inc.Bought 2,118 shares on 4/23/2024Ownership: 0.499%Massachusetts Wealth ManagementBought 2,509 shares on 4/19/2024Ownership: 0.387%Webster Bank N. A.Sold 1,470 shares on 4/16/2024Ownership: 0.048%Banque Cantonale VaudoiseBought 1,454 shares on 4/10/2024Ownership: 0.131%View All Institutional Transactions PBE ETF - Frequently Asked Questions How have PBE shares performed in 2024? Invesco Biotechnology & Genome ETF's stock was trading at $65.84 at the beginning of the year. Since then, PBE shares have decreased by 8.3% and is now trading at $60.3878. View the best growth stocks for 2024 here. What does PBE invest in? Invesco Biotechnology & Genome ETF is a equity fund issued by Invesco. PBE focuses on health care investments and follows the Dynamic Biotech & Genome Intellidex Index. The fund's investments total to approximately $243.96 million assets under management. What stocks does Invesco Biotechnology & Genome ETF hold? PBE invests in 34 holdings. Some of the stocks in their portfolio include Neurocrine Biosciences (NBIX), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), BioMarin Pharmaceutical (BMRN), Biogen (BIIB), Gilead Sciences (GILD), Bio-Techne (TECH), MannKind (MNKD) and Exelixis (EXEL). What is the management fee for Invesco Biotechnology & Genome ETF? Invesco Biotechnology & Genome ETF's management fee is 0.50% and has other expenses of 0.08%. The net expense ratio for PBE is 0.58%. What other stocks do shareholders of Invesco Biotechnology & Genome ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other Invesco Biotechnology & Genome ETF investors own include Pfizer (PFE), Intel (INTC), Align Technology (ALGN), Micron Technology (MU), Activision Blizzard (ATVI), DocuSign (DOCU), Inovio Pharmaceuticals (INO), Mastercard (MA), Hello Group (MOMO) and ONEOK (OKE). Who are Invesco Biotechnology & Genome ETF's major shareholders? Invesco Biotechnology & Genome ETF's stock is owned by a number of institutional and retail investors. Top institutional shareholders include YHB Investment Advisors Inc. (0.65%), Raymond James Financial Services Advisors Inc. (0.50%), Massachusetts Wealth Management (0.39%), Banque Cantonale Vaudoise (0.13%) and Webster Bank N. A. (0.05%). How do I buy shares of Invesco Biotechnology & Genome ETF? Shares of PBE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEARCA:PBE) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe World's First "$20 Trillion Drug?"Behind the MarketsMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invesco Biotechnology & Genome ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.